894 results on '"Xie, Sharon X."'
Search Results
152. TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia
153. Bias induced by ignoring double truncation inherent in autopsy‐confirmed survival studies of neurodegenerative diseases
154. Longitudinal progression of grey matter atrophy in non-amnestic Alzheimer’s disease
155. Acupuncture Versus Cognitive Behavioral Therapy for Insomnia in Cancer Survivors: A Randomized Clinical Trial
156. Divergent patterns of TDP‐43 and tau pathologies in primary progressive aphasia
157. Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders
158. A Comparison of Multiple Urine Markers for Interstitial Cystitis
159. NONBLADDER RELATED SYMPTOMS IN PATIENTS WITH INTERSTITIAL CYSTITIS
160. Meta-Analysis of Several Epidemic Characteristics of COVID-19.
161. P3‐406: DISTINCT LONGITUDINAL CORTICAL ATROPHY IN NON‐AMNESTIC COMPARED TO AMNESTIC ALZHEIMER'S DISEASE SUGGESTS DIFFERENT PATTERNS OF SPREADING PATHOLOGY
162. IC‐06‐03: DISTINCT LONGITUDINAL CORTICAL ATROPHY IN NON‐AMNESTIC COMPARED TO AMNESTIC ALZHEIMER'S DISEASE SUGGESTS DIFFERENT PATTERNS OF SPREADING PATHOLOGY
163. Older Adult Normative Data for the Sniffin’ Sticks Odor Identification Test
164. Occupational attainment influences longitudinal decline in behavioral variant frontotemporal degeneration
165. Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia
166. Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG)
167. The Kaplan–Meier method for estimating and comparing proportions in a randomized controlled trial with dropouts
168. APOE , thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease
169. Statins and Cognition in Parkinson’s Disease
170. Cox Regression Model with Doubly Truncated Data
171. Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration
172. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration
173. Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia
174. Neuropsychological Subgroups in Non-Demented Parkinson’s Disease: A Latent Class Analysis
175. Comparative effectiveness of electro-acupuncture versus gabapentin for sleep disturbances in breast cancer survivors with hot flashes: a randomized trial
176. Effects of the Insulin Sensitizer Metformin in Alzheimer Disease
177. Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases
178. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis
179. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial
180. Plasma ApoA1 Associates with Age at Onset and Motor Severity in Early Parkinson Disease Patients
181. Nonparametric Discrete Survival Function Estimation with Uncertain Endpoints Using an Internal Validation Subsample
182. Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD.
183. Genetic predictors of survival in behavioral variant frontotemporal degeneration.
184. Epilepsy in families: Age at onset is a familial trait, independent of syndrome.
185. Older Adult Normative Data for the Sniffin' Sticks Odor Identification Test.
186. Occupational attainment influences longitudinal decline in behavioral variant frontotemporal degeneration.
187. Turning apathy into action in neurodegenerative disease: Development and pilot testing of a goal-directed behaviour app.
188. CSF Apo-E levels associate with cognitive decline and MRI changes
189. Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases
190. Social epigenetics of racial disparities in aging.
191. Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype
192. Development and Validation of the Parkinson’s Disease Medication Beliefs Scale (PD-Rx)
193. The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease
194. Olfactory impairment predicts cognitive decline in early Parkinson's disease
195. CHoosing Options for Insomnia in Cancer Effectively (CHOICE): Design of a patient centered comparative effectiveness trial of acupuncture and cognitive behavior therapy for insomnia
196. An Alzheimer’s Disease-Derived Biomarker Signature Identifies Parkinson’s Disease Patients with Dementia
197. Amyloid‐Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia
198. Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors
199. DISTINCT LONGITUDINAL CORTICAL ATROPHY IN NON-AMNESTIC COMPARED TO AMNESTIC ALZHEIMER'S DISEASE SUGGESTS DIFFERENT PATTERNS OF SPREADING PATHOLOGY
200. Non-Alzheimer’s contributions to dementia and cognitive resilience in The 90+ Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.